Incidence and risk factors for acute graft-versus-host disease (aGVHD) in allogeneic hematopoietic stem cell transplantation (alloHSCT) in childhood.

被引：0
|
作者：
Prete, A
Zecca, M
Rondelli, R
Dini, G
Porta, F
Messina, C
Fagioli, F
Uderzo, C
Giorgiani, G
Locatelli, F
Pession, A
机构：
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
855
引用
收藏
页码：243A / 244A
页数：2
相关论文
共 50 条
  • [41] Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children
    Kondo, M
    Kojima, S
    Horibe, K
    Kato, K
    Matsuyama, T
    BONE MARROW TRANSPLANTATION, 2001, 27 (07) : 727 - 730
  • [42] Increase of Regulatory γδ T Cells Reduces the Incidence of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
    Gao, Li
    Xuan, Li
    Wu, Xiuli
    Fan, Zhiping
    Huang, Fen
    Yi, Zhangshan
    Li, Yangqiu
    Liu, Qifa
    BLOOD, 2016, 128 (22)
  • [43] Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide
    Canto, P. Asensi
    Gomez-Segui, I.
    Montoro, J.
    Montaner, M. Villalba
    Chorao, P.
    Alcaina, P. Solves
    Balsera, M. Santiago
    Madrid, P. Lloret
    Ruiz, J. Solis
    Pell-Ilderton, C. Sopena
    Campuzano, D. Martinez
    Serrano, P. Granados
    del Rio, J. Eiris
    Louro, A.
    Rebollar, P.
    Perla, A.
    Benavente, R.
    Comos, J. De la Rubia
    Sanz, M. A.
    Balaguer, A.
    Sanz, J.
    BONE MARROW TRANSPLANTATION, 2024, 59 (11) : 1577 - 1584
  • [44] Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation
    Hansen, John A.
    Chien, Jason W.
    Warren, Edus H.
    Zhao, Lue Ping
    Martin, Paul J.
    CURRENT OPINION IN HEMATOLOGY, 2010, 17 (06) : 483 - 492
  • [45] Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children
    M Kondo
    S Kojima
    K Horibe
    K Kato
    T Matsuyama
    Bone Marrow Transplantation, 2001, 27 : 727 - 730
  • [46] Sclerodermatous chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation:: incidence, outcome and risk factors
    Skert, C
    Patriarca, F
    Damiani, D
    Cerno, M
    Filì, C
    Geromin, A
    Sperotto, A
    Fanin, R
    BONE MARROW TRANSPLANTATION, 2005, 35 : S151 - S151
  • [47] Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Risk Factors and Spectrum of Infectious Complications
    Stoma, Igor
    Karpov, Igor
    Milanovich, Natalia
    Krivenko, Svetlana
    Iskrov, Igor
    Uss, Anatoly
    TRANSPLANTATION, 2018, 102 : S674 - S674
  • [48] Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease
    Yanez, L.
    Insunza, A.
    Ibarrondo, P.
    de Miguel, C.
    Bermudez, A.
    Colorado, M.
    Lopez-Duarte, M.
    Richard, C.
    Conde, E.
    TRANSPLANT INFECTIOUS DISEASE, 2015, 17 (05) : 761 - 767
  • [49] Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
    Nassar, Amr
    Elgohary, Ghada
    Elhassan, Tusneem
    Nurgat, Zubeir
    Mohamed, Said Y.
    Aljurf, Mahmoud
    JOURNAL OF TRANSPLANTATION, 2014, 2014
  • [50] Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Chen, Yi-Bin
    Shah, Nirav N.
    Renteria, Anne S.
    Cutler, Corey
    Jansson, Johan
    Akbari, Mona
    Chen, Chunlin
    Quadri, Syed
    Parfionovas, Andrejus
    Devine, Steven M.
    BLOOD ADVANCES, 2019, 3 (23) : 4136 - 4146
12345